$HEIA (-2,15%)
$EL (+0,14%)
$NUE (+0,6%)
$CDNS (+3,05%)
$WM (-0,79%)
$MSFT (+0,73%)
$V (+0,43%)
$OR (-0,52%)
$AZN (+0,17%)
$MRK (+0,33%)
$PG (-0,26%)
$SBUX (+1,05%)
$BCS (+0,56%)
$META (+0,52%)
$BABA (+1,49%)
$QCOM (-0,13%)
$AIR (+0,24%)
$HSBC (+0,87%)
$GSK (-3,35%)
$MBG (+0,6%)
$F (+7,3%)
$AAPL (+1,55%)
$AMZN (+1,75%)
$MA (-0,09%)
$7203 (+0,8%)
$SHEL (+0,08%)
$005930
$SNY (+4,68%)
$CMCSA (+0,1%)
$COIN (+10,01%)
$NET (+0,79%)
$XOM (-0,66%)
$CVX (-0,66%)
$CS (+0,18%)
$NTDOY (-1,63%)
$CL (-1%)
$DTG (+1,03%)
$UNH (+0,84%)
Discussão sobre SNY
Postos
2Quarterly figures 28.07-01.08

Sanofi reported earnings Q4 FY2024 results ended on December 31, 2024
- Revenue: €10.56B, +10.3% YoY at CER
- Net income: €683M vs -€555M in Q4 2023
- Business EPS: €1.31, -11.0% YoY at CER
- Full year revenue: €41.1B, +11.3% YoY at CER
CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."
🌱Revenue & Growth
- US sales: €5.15B, +13.3% YoY at CER
- Europe sales: €2.43B, +6.0% YoY at CER
- Rest of World: €2.98B, +8.8% YoY at CER
- Dupixent sales: €3.46B, +16.0% YoY at CER
- Vaccines sales: €2.18B, +10.8% YoY at CER
💰Profits & Financials
- Gross margin: 74.3%, -2.5pp YoY
- Business operating income: €2.08B, -7.7% YoY at CER
- Free cash flow: €2.34B, -25.5% YoY
- R&D expenses: €2.26B, +24.4% YoY
📌Business Highlights
- Received 14 regulatory approvals of medicines and vaccines in 2024
- Beyfortus achieved blockbuster status with €1.7B sales in first full year
- Plans to sell controlling stake in Opella consumer health business
🔮Future Outlook
- 2025 sales growth expected at mid-to-high single-digit percentage at CER
- Expects strong rebound in business EPS with low double-digit growth at CER
- Plans €5B share buyback program in 2025
- Dupixent sales expected to reach around €22B by 2030
Títulos em alta
Principais criadores desta semana
